Cervical Cancer Screening Coverage Criteria
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines BlueCross BlueShield of Tennessee coverage criteria for cervical cancer screening methods (Pap cytology, high‑risk HPV testing, co‑testing, and related reflex testing) and populations affected, including average‑risk, high‑risk, immunocompromised, HIV‑positive, and post‑hysterectomy individuals.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cervical Cancer Screening
Covered indications
Covered when the following age- and risk-based criteria are met:
See policy for definitions of immunocompromised (e.g., organ transplant, chronic immunosuppression).
Cytology preferred in this age group per policy reimbursement statements.
Policy states annual frequencies for these modalities in the reimbursement section.
High-risk exceptions to routine cessation are specified in the policy.
Reflex genotyping supported to inform need for colposcopy per policy.
Continued annual surveillance recommended in these scenarios.
Covered testing strategies and special-population guidance
Covered strategies and intervals supported by guideline recommendations:
Refer to patient risk and prior screening history for cessation decisions.
Guidance reflects ASCCP/consensus statements and is cited in policy.
Policy cites ACOG/ASCCP recommendations for reflex triage.
Adequate screening history is defined in policy (eg, 3 consecutive negative Pap smears or 2 negative HPV tests within 10 years).
Policy aligns with ASCCP/ACOG guidance for special-population management.
Covered screening and triage pathways
Coverage aligns with cited clinical guideline recommendations and includes conditional pathways by patient risk and resource setting.
Policy references ACOG statement restricting non‑FDA approved assays for primary screening.
HHS guidance cited in policy (BII).
HHS guidance details multiple acceptable management pathways and triage options.
ASCO resource‑stratified recommendations are cited for algorithm and follow-up intervals.
ASCO guidance for enhanced-resource contexts.
ASCO resource‑stratified guidance describes alternatives when HPV testing is not accessible.
Routine cervical cancer screening coverage is age- and risk-dependent. For average-risk individuals, the policy aligns with guideline-derived thresholds: do not initiate routine screening before age 21; individuals aged 21–29 are managed with cytology-focused strategies; and routine screening for many individuals stops after age 65 when they have an adequate screening history (for example, three consecutive negative Pap smears or two negative HPV tests within 10 years with the most recent within 5 years). Documentation of prior screening results and risk status is required to support coverage decisions.
Screening is not indicated for individuals who no longer have a cervix after a hysterectomy for benign disease. The policy explicitly states that cervical cancer screening "DOES NOT MEET COVERAGE CRITERIA" for individuals who underwent surgical removal of the uterus and cervix and have no history of cervical cancer or precancer, consistent with referenced guidance that screening is not helpful in women without a cervix.
HPV mRNA and non‑FDA‑approved HPV DNA assays are not acceptable as a stand‑alone primary screening modality unless there are sufficient, rigorous data supporting their primary‑screen use. The policy directs that such assays "should only be used as a cotest with cytology" for primary screening unless robust evidence supports otherwise.
Within the provided excerpt there are no additional explicit coverage exclusions beyond the age‑ and hysterectomy‑related items and test‑type limitations already described; procedural and billing codes are listed for reference but do not by themselves create exclusions.
Age-based rules summarized: do not screen individuals younger than 21. For individuals aged 21–29, cytology‑based screening is emphasized. For individuals aged 30–65, options include cytology, high‑risk HPV testing, or co‑testing per guideline intervals (see full policy for specific interval choices). Routine cessation of screening may be appropriate after 65 when there is an adequate prior screening history (eg, three negative Pap smears or two negative HPV tests within 10 years, with the most recent within 5 years), unless high‑risk factors indicate continued surveillance.
Rationale for discouraging screening before age 21 is based on low prevalence of lesions likely to progress and the potential harms of overdiagnosis, false positives, and overtreatment—effects that are particularly problematic for younger patients and may impact fertility and pregnancy. For older adults, guideline recommendations against routine screening after 65 rely on adequate prior negative screening, but the policy notes that individual risk factors (history of high‑grade lesions, prior cancer, in‑utero DES exposure, immunocompromise) warrant continued surveillance and may extend screening beyond this age.
Primary high‑risk HPV testing is discussed as an accepted strategy in referenced guidance where appropriate: several guideline bodies recognize primary hrHPV screening as an alternative to cytology‑based approaches and recommend age thresholds and rescreening intervals (for example, not before age 25 in some guidance and rescreening no sooner than every 3 years after a negative primary hrHPV screen). The policy directs reflex triage testing for positive HPV results and follows guideline pathways for management.
The excerpt does not include explicit statements phrased as 'not medically necessary' beyond the age‑based and post‑hysterectomy items already described; the policy provides 'does not meet coverage criteria' language for those scenarios and lists coding references separately.
Relevant Procedure and Test Codes
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44) |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed |
| 88141 | Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician |
| 88142 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision |
| 88143 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision |
| 88147 | Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision |
| 88148 | Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision |
| 88153 | Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision |
| 88164 | Cytopathology, slides, cervical or vaginal (the bethesda system); manual screening |
| 88165 | Cytopathology, slides, cervical or vaginal (the bethesda system); with manual screening and rescreening under physician supervision |
| G0476 | Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test. |
| P3000 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision. |
| P3001 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician. |
| Q0091 | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory. |
Provider Requirements and Billing Considerations
Benefit Verification Required
Benefit verification is required — coverage depends on the member's benefit at time of service. Medicare and Medicaid rules may differ; consult applicable state and federal regulations.
- Verify member eligibility and benefits before scheduling screening or HPV testing.
- Medicare/Medicaid may have specific coverage rules; follow applicable regulations.
Prior Authorization
No explicit prior authorization requirement is stated in the extracted sections.
- If institutional or local payer rules impose prior authorization, obtain it per that payer's process.
Procedure Codes Referenced
Procedure codes are provided for reference; use payer rules when submitting claims.
- Include appropriate clinical documentation when billing.
- Codes listed below are for reference and may not be exhaustive.
G0476 Requirement
Specific billing guidance: G0476 must be performed in addition to a Pap test when used for cervical cancer screening; failure to perform concurrent Pap testing may affect coverage.
Denial Triggers — Age and Hysterectomy
Denial triggers to watch for — age-based exclusions and post-hysterectomy status may result in noncoverage.
- Screening for individuals <21 years of age DOES NOT MEET COVERAGE CRITERIA.
- Routine screening for individuals >65 years with an adequate screening history DOES NOT MEET COVERAGE CRITERIA.
- Screening for individuals who have had a hysterectomy with removal of the cervix for benign disease and no history of cervical pre-cancer or cancer DOES NOT MEET COVERAGE CRITERIA.
Non-FDA-Approved HPV Tests
Non–FDA-approved HPV assays should not be used alone for primary screening; they may be used only as cotests or for reflex/management indications unless sufficient, rigorous data support primary use.
- Use FDA-approved high-risk HPV assays for primary screening.
- HPV mRNA and non-FDA-approved HPV DNA tests without FDA approval for primary screening should be limited to cotesting with cytology for management indications.
Clinical Triage Sequencing
Clinical triage and sequencing must be documented and followed: reflex testing from the same specimen, genotyping/cytology triage, repeat testing intervals, and colposcopy referral pathways.
- All positive primary HPV screening tests should have reflex triage testing (eg, reflex cytology) performed from the same specimen.
- If HPV16/18 positive, proceed to colposcopy if additional testing of the same sample is not feasible.
- If primary HPV positive with negative triage cytology, repeat HPV testing at 12 months; refer to colposcopy if repeat is positive.
- Surveillance after treatment for HSIL/CIN2-3/AIS: continue HPV testing or cotesting at 3-year intervals for at least 25 years; extend as clinically appropriate.
Required Clinical Documentation
Required clinical documentation must be present to support medical necessity and billing.
- Document patient age, risk status (eg, HIV, immunocompromised, DES exposure, organ transplant), prior screening history, and hysterectomy status.
- Include baseline tests, reflex/triage test results, follow-up plan and intervals (eg, 12‑month repeat, 3‑year surveillance), and rationale for colposcopy or continued surveillance.
- Retain laboratory reports showing HPV genotyping results (eg, HPV 16/18) and cytology findings.
Applicable Procedure Codes
Procedure code list (reference) — include HPV, cytology, and Pap screening codes when submitting claims.
- CPT/HCPCS codes referenced: 87623, 87624, 87625, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88164, 88175, 0500T, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, G0476, P3000, P3001, Q0091.
- Note: Procedure codes appearing in the policy are provided as general reference and may not be all-inclusive; follow current CPT/HCPCS guidance and payer billing rules.
Background and Rationale
Cervical cancer screening detects precancerous changes and cancer by combining cytology (Papanicolaou smear), high‑risk HPV molecular testing, and diagnostic follow‑up such as colposcopy when indicated. Cytology identifies cellular abnormalities, while hrHPV testing detects viral types most strongly associated with cervical neoplasia (eg, types 16 and 18). Primary hrHPV screening, co‑testing, and reflex genotyping or cytology triage are tools used in complementary ways: positive HPV results typically prompt reflex testing from the same specimen (eg, cytology or genotyping for HPV‑16/18) to determine need for colposcopy and treatment.
Key Terms and Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.